{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003801","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.340652+00:00","generated_at":"2026-05-28T05:10:50.043298+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction","bullets":["Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).","Normalized testosterone in 8/13 females; 6 of 11 impacted participants resumed menses during the 12-week study.","Total adrenal volume consistently reduced across all dose cohorts; polycythemia resolved in 5 of 6 impacted participants.","No treatment-related severe or serious AEs; no dose reductions or discontinuations; most common AEs were headache (7/28) and fatigue (5/28).","Crinetics plans to initiate a global Phase 3 pivotal trial in adults and a Phase 2b/3 pediatric study in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003801","json":"https://secwatch.observer/filing/0000950170-25-003801.json","markdown":"https://secwatch.observer/filing/0000950170-25-003801.md","text":"https://secwatch.observer/filing/0000950170-25-003801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/0000950170-25-003801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025003801/crnx-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:10:50.043298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}